Latest

3 stories

Hide weekly roundups

Friday, August 14

Quarterly updatebelapectin Galectin Therapeutics Inc

Galectin says FDA aligned on Phase 3 design for belapectin in MASH cirrhosis

The company reported second-quarter 2026 results and said it reached agreement with the FDA on key elements of a registrational Phase 3 trial, with protocol submission expected in the third quarter.

SEC filing

Tuesday, August 4

FinancingGalectin Therapeutics Inc

Galectin's chairman converts $105.8 million in debt into equity

Richard E. Uihlein swapped notes across five credit lines for 34,376,167 shares, cutting Galectin's debt load and lifting his voting stake to about 49.3%.

SEC filing

Tuesday, July 14

Galectin Therapeutics posts results for belapectin hepatic impairment PK study

Trial updatebelapectin Galectin Therapeutics Inc